



**C4X Discovery Holdings plc**  
("C4XD", "C4X Discovery" or the "Company")

## **C4X Discovery forms Drug Discovery Advisory Network**

*World-renowned drug discovery experts to advance C4XD capabilities*

**2 September 2019** – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Robin Carr, a renowned industry veteran who has worked at GSK and Astex, is to head up and form a C4XD Drug Discovery Advisory Network.

The Advisory Network will bring together small molecule drug discovery and development experts from across the globe. It has been formed to harness industry expertise to build on C4XD's drug discovery capabilities and attract valuable relationships that have the potential to advance its goal of becoming the world's most productive drug discovery company. Robin and his team will act as ambassadors for C4XD within the Biotech and Pharmaceutical community, building awareness of C4XD's technologies, capabilities and business. Through their extensive relationships and industry knowledge, they will identify pioneering complementary drug discovery technologies and collaborators that have the potential to accelerate or improve delivery of C4XD's portfolio.

**Clive Dix, Chief Executive Officer of C4XD, said:** *"We are delighted to announce the formation of our Advisory Network and to be working closely with prestigious world leading experts in drug discovery. As part of our strategy to become the world's most productive drug discovery company, we are continually enhancing both our network and expertise. As international thought leaders, the Advisory Network's deep industry expertise will enable us to accelerate progress of our portfolio and we are particularly proud that Robin will be Chair. Under Robin's guidance, we believe the Advisory Network will advance our vision and reputation within the industry."*

**Robin Carr, added:** *"C4XD is an inspiring young company at the forefront of drug discovery with cutting edge technologies and scientists of the highest calibre. Their openness to collaboration and working with complementary technologies creates a new frontier in bringing novel approaches to the creation of future medicines. I am honoured and excited to be working with the C4XD team and to building the Advisory Network that will add value in an innovative and collaborative way."*

### **Chair of the C4XD Drug Discovery Advisory Network – Robin Carr**

Robin has thirty years of experience in drug discovery and has held senior roles in Glaxo Wellcome, GSK and Astex Therapeutics. At GSK, he was senior Vice President of Drug Design and Selection and held global responsibility for GSK's small molecule and biopharm drug discovery platforms. At Astex Therapeutics, Robin was VP Drug Discovery, with responsibility for its internal and partnered discovery programmes.

Robin's scientific focus is innovative approaches to small molecule drug discovery, specifically fragment-based discovery, DNA encoded libraries, covalent drug discovery, protein degradation and the integration of chemical technologies into structure and predictive modelling-based drug design.

During his career, Robin has worked on seven small molecule programmes that have progressed into the clinic, of which, two have achieved approval within oncology. Robin has published over 40 peer reviewed papers and patents.

Robin has a PhD in Chemistry from Northwestern University and a BSc in Organic Chemistry from Imperial College, London.

Further Advisory Network members will be announced in due course.



- Ends -

## Contacts

### **C4X Discovery Holdings**

Mo Noonan, Communications

+44 (0)787 6444977

### **Panmure Gordon (UK) Limited (NOMAD and Broker)**

Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

James Stearns (Corporate Broking)

### **C4X Discovery Media – Consilium Strategic Communications**

Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

## Notes to Editors:

### **About C4X Discovery**

C4X Discovery (C4XD) aims to create the world's most productive drug discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to \$294m.

C4XD has a state-of-the-art suite of proprietary technologies across the drug discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.

For additional information please go to: [www.c4xdiscovery.com](http://www.c4xdiscovery.com)